373 related articles for article (PubMed ID: 22861200)
1. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
2. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
[TBL] [Abstract][Full Text] [Related]
3. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia.
Hassall E; Owen D; Kerr W; Sturby T; Richardson P; El-Serag H
Aliment Pharmacol Ther; 2011 Apr; 33(7):829-36. PubMed ID: 21320136
[TBL] [Abstract][Full Text] [Related]
4. Hypergastrinemia and gastric enterochromaffin-like cells.
Bordi C; D'Adda T; Azzoni C; Pilato FP; Caruana P
Am J Surg Pathol; 1995; 19 Suppl 1():S8-19. PubMed ID: 7762739
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
6. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?
Waldum HL; Hauso Ø; Brenna E; Qvigstad G; Fossmark R
Scand J Gastroenterol; 2016 Jul; 51(7):767-73. PubMed ID: 26872579
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
8. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
9. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
10. Histamine metabolism of gastric carcinoids in Mastomys natalensis.
Kölby L; Wängberg B; Ahlman H; Modlin IM; Nilsson O
Yale J Biol Med; 1998; 71(3-4):207-15. PubMed ID: 10461353
[TBL] [Abstract][Full Text] [Related]
11. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
12. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
13. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
14. Changes in gene expression of gastric mucosa during therapeutic acid inhibition.
Nørsett KG; Laegreid A; Kusnierczyk W; Langaas M; Ylving S; Fossmark R; Myhre S; Falkmer S; Waldum HL; Sandvik AK
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):613-23. PubMed ID: 18679062
[TBL] [Abstract][Full Text] [Related]
15. [Type 1 carcinoids and ECL-cell hyperplasia of the gastric mucosa].
Stachura T; Strzałka M; Bolt L
Przegl Lek; 2003; 60(12):782-8. PubMed ID: 15058016
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
17. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat.
Mattsson H; Havu N; Bräutigam J; Carlsson K; Lundell L; Carlsson E
Gastroenterology; 1991 Feb; 100(2):311-9. PubMed ID: 1985029
[TBL] [Abstract][Full Text] [Related]
18. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
[TBL] [Abstract][Full Text] [Related]
19. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
20. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.
Waldum HL; Qvigstad G; Fossmark R; Kleveland PM; Sandvik AK
Scand J Gastroenterol; 2010 Apr; 45(4):389-94. PubMed ID: 20001749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
